...basket of gene editing stocks.Gene editing companies CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine Inc. (NASDAQ:EDIT), Intellia Therapeutics Inc....
...or visual content" frameborder="0" scrolling="no" style="width:100%;height:600px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Stephen Hansen CRISPR Therapeutics AG Intellia Therapeutics Inc. Editas...

...developing in vivo delivery technologies, while others have been signing deals to build their delivery toolboxes.Intellia Therapeutics Inc....
...content" frameborder="0" scrolling="no" style="width:100%;height:550px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Lauren Martz Beam Therapeutics Inc. CRISPR Therapeutics AG Intellia Therapeutics Inc. Editas...

...current valuation of the Phase I/II company is over $11 billion. Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc....
...content" frameborder="0" scrolling="no" style="width:100%;height:600px;" sandbox="allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation"> Lauren Martz Editas Medicine Inc. CRISPR Therapeutics AG Intellia Therapeutics Inc....

...disease (SCD), which don’t require the complex infrastructure needed for ex vivo gene therapies. The pharma and Intellia Therapeutics Inc....

...rights to the foundational CRISPR-Cas9 IP to Intellia Therapeutics Inc....

...Plasma kallikrein Danielle Golovin KVD900 ATN-249 NTLA-2002 Kalbitor, ecallantide (CB-500,929, DX-88, EPI-KAL2, FV2302) Takhzyro (lanadelumab, lanadelumab-flyo, SHP643, dx-2930) KVD824 KalVista Pharmaceuticals Inc. Attune Pharmaceuticals Inc. Intellia Therapeutics Inc. Takeda...

...editing pioneers Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc....

...elevated safety concerns around off-target edits. In November, Intellia Therapeutics Inc....

...editing. The first systemically delivered therapy, NTLA-2001 from Intellia Therapeutics Inc....
...undisclosedCEO: Mary Haak-FrendschoPatents: None issued Lauren Martz Spotlight Therapeutics Inc. Intellia Therapeutics Inc. Editas...

...CRISPR therapies for sickle cell disease. On Monday, Intellia Therapeutics Inc....
...of Intellia’s grant is undisclosed.TARGETSTTR – Transthyretin Lauren Martz NTLA-2001 Intellia Therapeutics Inc. Regeneron...